MARVELLA GARCIA: Open Payments
NPI 1164145751 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,100 in 63 payments from 11 companies in 2025. Trend: 2023 $299 · 2024 $1,622 · 2025 $1,100
Food & beverage: $1,100
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $219 |
| ABBVIE INC. | 17 | $170 |
| Teva Pharmaceuticals USA, Inc. | 8 | $160 |
| Otsuka America Pharmaceutical, Inc. | 11 | $153 |
| Lundbeck LLC | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
| Neurocrine BioSciences, Inc. | 1 | $39 |
Products named: REXULTI, CAPLYTA, VRAYLAR, UZEDY, TRINTELLIX, Auvelity, COBENFY, SPRAVATO.
Industry payments across TX — which companies pay providers there.
